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On the observation of Hypokalemia in Covid-19
Amelia Carolina Sparavigna
Politecnico di Torino
Hypokalemia is a low level of potassium in the blood serum. Here a survey of literature about the
observation of Hypokalemia in Covid-19. In particular we consider the study published in a
MedRvix preprint "Hypokalemia and clinical implications in patients with coronavirus disease 2019
(COVID-19)".
Keywords: Hypokalemia, Covid-19.
Torino, May 13, 2020 - DOI: 10.5281/zenodo.3824113
In [1,2], we have considered some literature about Covid-19 Cytokine Release Syndrome, known as
"cytokine storm", of drugs used for it and of a the possible use of Vitamin D for Covid-19.
Here we consider literature about the observation of Hypokalemia in Covid-19.
"Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not
typically  cause  symptoms.  Symptoms  may  include  feeling  tired,  leg  cramps,  weakness,  and
constipation. Low potassium also increases the risk of an abnormal heart rhythm, which is often too
slow and can cause cardiac arrest.  ...  Mild hypokalemia (>3.0 mEq/l)  may be treated by eating
potassium-containing foods or by taking potassium chloride supplements  ... Eating potassium-rich
foods  may  not  be  the  optimal  method  for  correcting  low  potassium  ...  Potassium  chloride
supplements by mouth have the advantage of containing precise quantities of potassium, ...  the
potential  for  side-effects  including  nausea  and abdominal  discomfort.  Potassium bicarbonate  is
preferred  when  correcting  hypokalemia  associated  with  metabolic  acidosis."
https://en.wikipedia.org/wiki/Hypokalemia  (in  Italiano,  Ipokaliemia  oppure  Ipopotassiemia.
Attenzione:  "Un eccesso di cloruro di potassio è tossico,  può provocare iperkaliemia,  aritmie e
morte cardiaca improvvisa". https://it.wikipedia.org/wiki/Cloruro_di_potassio#Precauzioni )
Here some news and literature about Hypokalemia in Covid-19.
News - "Covid-19 Research Updates: Chinese Study Reveals That Hypokalemia Present In Almost
All Covid-19 Patients". Source: Covid-19 Research  Mar 09, 2020  - "Covid-19 Research: A new
research study by researchers from Wenzhou Medical University in Zhejiang province lead by Dr
Dong  Chen  revealed  that  almost  all  Covid-19  patients  exhibited  hypokalemia  and  that
supplementation with potassium ions was one of the many factors that assisted in their recovery ...
It was found that as the SARS-CoV-2 coronavirus attacks human cells via the ACE2 (Angiotensin-
converting enzyme-2) receptors, it also attacks the renin–angiotensin system (RAS), causing low
electrolyte levels in particularly potassium ions. The study involving 175 patients in collaboration
with Wenzhou Hospital found that almost all patients exhibited hypokalemia and for those who
already  had  hypokalemia,  the  situation  even  drastically  worsened  as  the  disease  progressed.
However, it was found from the study that patients responded well to potassium ion supplements
and had a better chance of recovery". https://www.thailandmedical.news/news/covid-19-research-
updates-chinese-study-reveals-that-hypokalemia-present-in-almost-all-covid-19-patients
This  news  is  mentioning  the  following  research  article  entitled  "Hypokalemia  and  Clinical
Implications  in  Patients  with  Coronavirus  Disease  2019  (COVID-19)"  [3].  Abstract  tells  that
"SARS-CoV-2 binds angiotensin I converting enzyme 2 (ACE2) of renin-angiotensin system (RAS)
and  causes  prevalent  hypokalemia".  "The  patients  with  COVID-19  were  classified  into  severe
hypokalemia,  hypokalemia,  and  normokalemia  group.  The  study  aimed  to  determine  the
relationship  between  hypokalemia  and  clinical  features,  the  underlying  causes  and  clinical
implications of hypokalemia". The results given in [3] are the following. "By Feb 15, 2020, 175
patients  with  COVID-19  (92  women  and  83  men;  median  age,  46  [IQR,  34-54]  years)  were
admitted to hospital in Wenzhou, China, consisting 39 severe hypokalemia-, 69 hypokalemia-, and
67 normokalemia patients. Gastrointestinal symptoms were not associated with hypokalemia among
108  hypokalemia  patients  (P>0.05).  Body  temperature,  CK,  CK-MB,  LDH,  and  CRP  were
significantly associated with the severity of hypokalemia (P<0.01). 93% of severe and critically ill
patients had hypokalemia which was most common among elevated CK, CK-MB, LDH, and CRP.
Urine K+ loss was the primary cause of hypokalemia. severe hypokalemia patients was given 3
g/day, adding up to an average of 34 (SD=4) g potassium during hospital stay. The exciting finding
was that patients responded well to K+ supplements when they were inclined to recovery". The
conclusions of the researchers is that "Hypokalemia is prevailing in patients with COVID-19. The
correction of hypokalemia is challenging because of continuous renal K+ loss resulting from the
degradation of ACE2. The end of urine K+ loss indicates a good prognosis and may be a reliable,
in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system". 
Data from [3]  had been used in  [4],  where the authors  "compared the prevalence  of  abnormal
clinical indices of the paediatric patients with previously reported data for 175 adults with COVID-
19 in Wenzhou," [3] "44 paediatric patients with SARS in Hong Kong, and 167 Chinese paediatric
patients with H1N1 influenza".
Work [3] is mentioned in [5], where the authors tell "Urine potassium loss was the primary cause of
hypokalemia, and it has been reported that SARS-CoV-2 binds angiotensin I converting enzyme 2
(ACE2) on the cell membrane A and promote the degradation of ACE2, and thus decreases the
counter-act of ACE2 on renin–angiotensin system (RAS). This mechanism increase reabsorption of
sodium and water,  and increase the excretion of potassium (12) [3].  The authors [in MedRxiv]
reported  that  the correction  of  hypokalemia  was challenging because of  the continuous loss of
potassium, and for the cardiovascular effects and neurohormonal activation, and other vital organs
by hypokalemia".
Work [3] is mentioned in [6]. "Electrolyte imbalances can occur in any critical systemic illness and
precipitate  arrhythmias,  esp.  in  patients  with  underlying  cardiac  disorder.  There  is  particular
concern  about  hypokalemia  in  COVID-19,  due  to  interaction  of  SARS-CoV-2  with  renin-
angiotensin-aldosterone system. Hypokalemia increases vulnerability to various tachyarrhythmias".
Work [3] is mentioned in [7]. In a quite long section of [7] it is told that "Patients with more severe
COVID-19 are reported to have hypokalemia and higher blood pressure as compared with those
with milder COVID-19 that would support a role for a stimulated ANG II-AT1 receptor axis (6).
Current clinical data on the ACE2-Ang-(1–7) pathway, however, are quite limited relative to the
experimental data, especially in regard to the effects of ACEI and ARB.   Furthermore, the existing
evidence,  though  novel  and  insightful,  often  comes  from smaller  cross-sectional  observational
studies with incomplete RAAS measurements that cannot fully account for potential sources of bias
and confounding".
News  -  "Do  ACE  inhibitors  increase  SARS-CoV-2  binding  to  ACE2?"  -  by  Liji  Thomas,
https://www.news-medical.net/news/20200420/Do-ACE-inhibitors-increase-SARS-CoV-2-binding-
to-ACE2.aspx 20 April 2020. "Dysregulation of Ang II - Many patients with COVID-19 have been
reported to develop hypokalemia (low potassium). This is not due to any apparent loss through the
gut and is proportional to the severity of the disease. However, the report on this condition did not
mention the prevalence of the use of RAAS inhibitors as a confounding factor. Some see this as a
complication of RAAS dysfunction in COVID-19. They suggest that the loss of potassium through
the kidneys may be due to higher Ang II levels due to the binding of the SARS-CoV-2 virus to
ACE2 receptors. This could, they think, prevent the action of ACE2 in maintaining the balance
between ACE2 and Ang II levels. The ARB losartan was found to improve lung injury in mice by
reducing levels of Ang II. When the genes for ACE2 are not expressed in a mouse model, and the
knockout mouse, as it is called, is exposed to viral influenza, the affected mice were sicker and less
likely  to  survive.  This could  indicate  the protective  role  of  ACE2 in stabilizing  Ang II  levels,
converting the latter to Ang 1-7".
Work [3] in mentioned in [8]. "Furthermore, a recently concluded study showed that severe and
critically ill patients with COVID-19 had a higher prevalence of hypokalemia that resulted from
renal  potassium  wasting.  This  can  be  explained  by  downregulation  of  ACE2  following  viral
intrusion resulting in decreased degradation of angiotensin-II, increased aldosterone secretion and
subsequent increased urinary potassium loss. In fact early normalization of serum potassium has
been proposed to be a predictor of good prognosis in COVID-19 [16]. Thus, ACE2 overexpression,
while facilitating entry of SARS-CoV-2, is unable to protect against lung injury as the enzyme gets
degraded by the virus (see Fig. 1) ".
Work [3] is mentioned in [9]. " In early COVID-19 studies, some evidence has been provided that
electrolyte disorders may also be present upon patients’ presentation, including sodium, potassium,
chloride and calcium abnormalities. Others have postulated that patients with more severe COVID-
19 tend to display a higher proportion of hypokalaemia at baseline compared with those with less
severe forms of disease. [3] Such electrolyte disturbances have important implications not only for
patient  management  but  also  for  identifying  potential  pathophysiologic  mechanisms  underlying
COVID-19, that could drive novel therapeutic opportunities. Nevertheless, limited sample sizes and
heterogeneity in electrolyte reporting have limited interpretations to-date. Therefore, ...".
In [10], it is told that "There is particular concern about hypokalemia in COVID-19 disease; as a
result interaction of SARS-CoV2 with the RAS system. Hypokalemia is well known to increases
vulnerability  to  various  kinds  of  arrhythmia".  And  also  "There  is  particular  concern  about
hypokalemia in COVID-19 disease; as a result interaction of SARS-CoV2 with the RAS system". In
[10], the reference given points to [11], but it seems it is not the proper one. In any case, in [10] it is
told that "Hypokalemia is well known to increases vulnerability to various kinds of arrhythmia.
Recommendations for the management of arrhythmias follows a similar pattern for non-COVID
patients with optimization of electrolytes, avoiding triggers including medication modification and
EKG monitoring for patients with long QTc or on medications known to prolong QTc interval".
Ref.10 mentions [12].
In [11], it is told, about Covid-19, that "Much has been learnt in the course of preceding epidemics,
including severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS),
and H1N1 influenza,  and it  is  now recognized  that  their  overall  health  burden may be  under-
estimated  since  extra-pulmonary  manifestations  are  frequent.  Acute  and  chronic  cardiovascular
complications of pneumonia are common and result from various mechanisms, including relative
ischaemia, systemic inflammation, and pathogen-mediated damage. There is, however, only limited
published data concerning cardiovascular presentations in the wake of viral epidemics. The present
COVID-19 outbreak emphasizes the need for greater awareness of the immediate and long-term
cardiovascular  implications  of  viral  infection  and the significant  gaps in  knowledge that  future
research will need to address".
Let us conclude with news.
News - «Terapie a casa, un mix di farmaci Potassio e magnesio per il cuore» Per fare chiarezza su
come  affrontare  l’infezione,  Regione  Lombardia  ha  istituito  una  Rete  per  la  valutazione
farmacologica e terapeutica dei pazienti con Covid-19 - Articolo di Laura Cuppini - 2 Aprile 2020 -
https://www.corriere.it/salute/malattie_infettive/20_aprile_02/terapie-casa-mix-farmaci-potassio-
magnesio-il-cuore-82314fac-744a-11ea-b181-d5820c4838fa.shtml
It  is  an  interview  with  Francesco  Scaglione,  Università  degli  Studi  di  Milano  and  Ospedale
Niguarda. The question is "Quali sono quindi i farmaci che funzionano davvero? «Siamo partiti da
una riflessione: un ruolo-chiave è quello del meccanismo di eccessiva infiammazione associato a
una  sindrome da  rilascio  citochinico  -  for  what  concern  the  therapy  -   La  combinazione  è  la
seguente: idrossiclorochina (un vecchio farmaco antimalarico), azitromicina (antibiotico con effetto
immunomodulante) e celecoxib, antinfiammatorio con attività nei confronti della ciclo-ossigenasi di
tipo  2  (COX-2,  enzima  che  determina  il  rilascio  di  citochine).  ...  Tutti  i  pazienti  dovrebbero
assumere  supplementi  di  potassio  e  magnesio  per  scongiurare  il  rischio  di  aritmie  cardiache,
possibile effetto collaterale della combinata idrossiclorochina-azitromicina».
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